Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2024.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.
Hipertens Riesgo Vasc
January 2025
Hospital Pharmacist Manager, Pharmaceutical Department, Asl Napoli 3 Sud., Italy. Electronic address:
Statins are crucial for both the prevention and management of atherosclerotic cardiovascular disease (ASCVD). However, even with optimized statin therapy, a significant residual risk of ASCVD remains, highlighting the need for innovative approaches to lipid-lowering therapies (LLT) that more effectively target low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins. Recently, novel pharmacologic agents have been introduced for the management of dyslipidemia.
View Article and Find Full Text PDFEffects of pre-pregnancy body mass index on cardiometabolic biomarkers in pregnant emirati women.
Reprod Health
December 2024
Departments of Pediatrics, United Arab Emirates University, Al-Ain, United Arab Emirates.
Background: To study effect of pregnancy on obese women's maternal cardiometabolic biomarkers as a signature for maternal morbidity and complications.
Methods: This cross-sectional cohort study involved pregnant Emirati women who had regular menstrual cycles and had normal blood pressure. Pre-pregnancy body mass index was calculated using height and weight measurements recorded within three months before current pregnancy.
Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis.
Nutr Metab Cardiovasc Dis
October 2024
Department of Pharmacy, Hebei Medical University Third Hospital, No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang, Hebei, China. Electronic address:
Aims: To evaluate the efficacy and safety of inclisiran in the treatment of hypercholesterolemia.
Date Synthesis: Randomized controlled trials comparing inclisiran with a placebo were searched until April 2024. Overall, 8 studies involving 4947 patients were included.
Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis.
Coron Artery Dis
December 2024
Department of the Second Clinic, The 940 Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou, Gansu Province, China.
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease due to its unique apo(a) component and its association with atherosclerosis and thrombogenesis. This meta-analysis was conducted to evaluate the effects of PCSK9 inhibitors on major adverse cardiac events (MACE) and Lp(a) levels in patients with coronary heart disease.
Methods: Randomized controlled trials (RCTs) were systematically searched in PubMed, the Cochrane Library, and other databases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!